Scynexis (SCYX) Preferred Stock Liabilities (2013 - 2014)
Scynexis' (SCYX) quarterly Preferred Stock Liabilities came in at $28.1 million in Q1 2014, little changed quarter-over-quarter from $28.1 million in Q4 2013.
Powered by 
Analysis
Scynexis (SCYX) Preferred Stock Liabilities (2013 - 2014) Analysis & Trends
Scynexis (SCYX) has reported Preferred Stock Liabilities for 2 consecutive years, with $28.1 million the latest figure, recorded in Q1 2014.
- For the quarter ending Q1 2014, Preferred Stock Liabilities changed N/A year-over-year to $28.1 million; the trailing twelve-month figure through Mar 2014 stood at $28.1 million (changed N/A YoY), and the FY2013 full-year result was $28.1 million, changed N/A from the prior year.
- Preferred Stock Liabilities steadied at $28.1 million in Q1 2014 per SCYX's latest filing, from $28.1 million in the prior quarter.
- Across five years, Preferred Stock Liabilities topped out at $28.1 million in Q4 2013 and bottomed at $28.1 million in Q4 2013.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | - |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | - |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | - |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | - |
| 10 | Scynexis | 58.41 Mn | -56.29 Mn | - | - |